hepatocellular carcinoma

EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging

EASL 2026 highlights the evolving role of non-invasive diagnostics in liver disease, offering improved accuracy for fibrosis and steatosis assessment.

MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026

EASL 2026 data indicates non-invasive markers may reduce liver biopsy necessity for MASH diagnosis, offering a less burdensome alternative.

ATM Germline Mutations and Liver Adenomas in Adolescents: A Clinical Reminder

Young patients presenting with hepatocellular adenomas, especially in the absence of typical risk factors, warrant careful consideration for underlying germline mutations. Heightened vigilance and appropriate genetic testing can significantly impact surveil...